Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Durability of Immune Response
Are you currently facing unpredictable long-term efficacy, waning serum antibody titers, and challenges in translating systemic responses to mucosal protection? Our NHP Efficacy and Durability Services help you engineer and validate durable, multi-layered immune protection through longitudinal sampling, advanced cellular omics profiling, and sophisticated modeling of tissue-resident memory cell populations.
NHP Ensure Your Next Vaccine Delivers Lasting Protection!
Addressing waning efficacy and unpredictable long-term protection in advanced biotherapeutics, NHP models are vital for translating transient systemic responses into durable, tissue-resident immune memory that protects against both infection and severe disease.
Overview of NHP Applications
What Are Our Research Areas?
The central challenge in vaccinology and infectious disease research has shifted from simply generating antibodies to establishing durable, protective immune memory. This requires moving beyond traditional serum assays to analyze the cellular and tissue-level events that dictate a response's lifespan. Preclinical research must now focus on characterizing the formation, persistence, and location of Long-Lived Plasma Cells (LLPC) in the bone marrow and Tissue-Resident Memory (TRM) cells in mucosal sites. Furthermore, the complex interplay between the chosen vaccine vector and Preexisting Immunity must be resolved using models that accurately reflect human immunological barriers and tissue structure. Creative Biolabs' NHP platform is engineered to meet these precise, high-resolution requirements for modern durable vaccine development.
Why Choose Us?
NHP models are the gold standard for validating vaccine durability and complex immune interactions because they uniquely bridge the gap between rodent models and human clinical trials. Creative Biolabs leverages these advantages:
- Genetic/Immunological Similarities: NHPs share critical genetic and immunological pathways with humans, including the composition and function of lymph nodes, bone marrow niches, and complex mucosal immune systems (e.g., IgA function, T-cell repertoire), which are essential for modeling durability.
- Modeling Complex Delivery: NHPs allow for the precise evaluation of various delivery routes (intramuscular, intravenous, airway/intranasal) and the measurement of localized immune responses (e.g., bronchoalveolar lavage, nasal washes) that are critical for achieving mucosal immunity.
- Data Types for Regulatory Submissions: Our platform generates the Pharmacokinetic (PK), Anti-Drug Antibody (ADA), Neutralizing Antibody (NAb), and advanced flow cytometry/multi-omics data necessary to define a durable, protective immune correlate.
Fig.1 Induction of neutralizing breadth via adjuvanted H1 stem protein vaccination in NHPs.1
Key Applications
Nonhuman Primates provide the most translational platform for dissecting the mechanisms of durable protection and optimizing next-generation vaccine platforms. Contact Creative Biolabs today to discuss your specific durability study needs.
- Mapping TRM and LLPC Formation: NHPs enable the longitudinal study of specialized cellular compartments crucial for lasting immunity. This includes tracking the differentiation and long-term residency of LLPCs in bone marrow aspirates and characterizing TRM T and B cells established in mucosal tissues following vaccination, providing data on where the memory resides and how long it lasts.
- Optimizing Delivery to Bypass Preexisting Immunity: The NHP model is indispensable for demonstrating the efficacy of non-systemic delivery routes. Studies in NHPs show that, unlike intramuscular injection, airway (intranasal/intratracheal) delivery of viral vectors can successfully bypass high systemic neutralizing antibody (NAb) titers, ensuring vector access to target cells and leading to protective immunity.
- Evaluating Vaccine Efficacy and Platform Durability under Challenge: NHP challenge models are used to measure the ultimate protective threshold. We assess the quality and breadth of protection, distinguishing between preventing infection versus protecting against severe disease, and measuring the longevity of the immune response over extended post-vaccination periods.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides an end-to-end, high-resolution NHP service platform, focusing on sampling hard-to-access immune compartments and delivering multi-omic analysis to define durable immunity.
| Service Capability | Corresponding Application Area |
| PBMCs & Immune Cells Collection & Biobanking | Provides access to peripheral and central immunity cells, including lymphocytes and mucosal fluid samples. |
| Infectious Diseases Model Development | Allows for lethal or sub-lethal challenge studies to measure the in vivo correlate of protection and durability. |
| Advanced Therapy Efficacy Studies: Vaccine Challenge & Protection Studies | Determination of minimum protective concentrations and efficacy in passive immunization and therapeutic delivery models. |
| ADA/Immunogenicity Testing | Essential for measuring both systemic and mucosal NAb levels to validate Bypass Preexisting Immunity-bypassing strategies. |
Translational Impact
By utilizing NHP models, you gain definitive proof-of-concept data that directly addresses major clinical failure points, particularly those related to longevity and delivery. NHP data on mucosal immunity and systemic NAb evasion provide critical evidence to support advanced delivery platforms and are often required for IND submissions for vector-based therapies. Early detection of vector-related toxicity or immunogenicity in NHPs, combined with our advanced multi-omics profiling, allows for candidate de-selection or modification, which translates directly into a reduced risk of costly Phase I and Phase II clinical trial failures. Furthermore, generating data that offers a more reliable, data-driven forecast of vaccine half-life and boosting schedules, ensuring that your product delivers on its promise of long-term protection.
Frequently Asked Questions
Q: What is the resolution of your cellular memory analysis?
A: We employ advanced multi-parameter flow cytometry and high-resolution cellular transcriptomic profiling on specialized NHP samples (e.g., bone marrow, lymph node). This high resolution allows us to not only identify memory cell lineages but also to characterize their distinct functional states and transcriptional programs that dictate true longevity, giving you a functional blueprint of durable immunity.
Q: What NHP sample types are critical for accurately measuring mucosal immunity?
A: Measuring local immunity requires specialized collection. We routinely perform bronchoalveolar lavage, nasal washes, and gut biopsy sampling to collect the low-titer antibodies and the essential TRM cells. This ensures that the measured mucosal immune response is truly localized and not just a spillover from the systemic circulation.
Q: How long can you track the durability of the immune response in NHPs?
A: Our NHP models are designed for longitudinal, multi-year studies. We establish customized, repeat sampling schedules that allow us to accurately model the kinetics of antibody decline and the subsequent plateau phase, which is maintained by LLPCs and is the true measure of durability, significantly extending beyond the typical 6-month preclinical window.
Q: What is the typical turnaround time for an integrated durability report?
A: Turnaround time is highly dependent on the study's duration and complexity (e.g., the time needed to observe the plateau phase of immunity). However, for the bioanalysis and multi-omics data, we strive for maximum efficiency. Preliminary PK/ADA and immunogenicity reports are delivered within weeks of sample collection, and our Integrated Bioinformatics Report—linking cellular memory, vector copy number, and protection data—is provided immediately upon completion of the final assay to accelerate your decision-making.
Contact Us
Creative Biolabs is the industry leader in leveraging the Nonhuman Primate model to address the most complex challenges in vaccinology: achieving and validating the durability of immune responses. Contact us and we provide the high-resolution tissue sampling, specialized challenge models, and integrated multi-omics analysis required to transform transient responses into lasting, protective memory.
Reference
- Swart, Maarten et al. "Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen." NPJ vaccines vol. 8,1 176. 11 Nov. 2023. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41541-023-00772-1